FDA approves expanded label for 177Lu-PSMA-617 in mCRPC
Study of Oligorecurrent Prostate Cancer Finds Winning Combination
Researchers explore steam treatment for prostate cancer
MyProstateScore version 2.0 may help men avoid unnecessary biopsy
AI-assisted HIFU for Prostate Cancer
Governor Hobbs proclaims September 2024 Arizona Prostate Cancer Awareness Month
Radioactive drugs strike cancer with precision
HRR Testing Underused in mCRPC
Patient Selection for Radioligand Therapy
Plant-Based Diets Tied With Lower Prostate Cancer Progression Risk, Better QOL
BREAKING NEWS: PCF Screening Guidelines for Black Men Now Published
Change the Odds initiative to bridge the gap in cancer care disparities
PCF: Know your risk, spread the word
US Dept. of Defense: Early screening is important for detection and treatment of prostate cancer
SMYD3 enzyme role in prostate cancer
HPV infections increase Prostate Cancer risk
New cancer treatment from inside the prostate gland
Personalized dosing improves patient outcomes
FDA approves talazoparib plus enzalutamide for HRR gene–mutated mCRPC
FDA approves new PSMA imaging agent
Important pending Prostate Cancer legislation that can affect you
FDA approves New Jersey Pluvicto Production
IsoPSA could eliminate need for biopsy
NIH declines to force lower priceon Xtandi
Let's support our "sisters" battling Triple-Negative Breast Cancer/BRCA1 mutation
New Cancer Data Spark Outcry From Patient Advocates
Targeting a single enzyme can kill prostate cancer cells
Cedars-Sinai Blood Test Detects and Profiles Prostate Cancer
Advanced Prostate Cancer rates on the rise
ACS's IMPACT initiative focuses on Prostate Cancer in Black men
Metastasis-Directed Therapy beneficial in Oligometastatic Prostate Cancer
Researchers identify new therapeutic approach against treatment-resistant prostate cancer
New genetic test for early detection
Test to Predict Prostate Cancer Agressiveness
Prostate Cancer Markers Help Individualize Care
FDA approves lu177 treatment for men with advanced prostate cancer
Radium-223 w/ Enzalutamide could increase life expectancy in mCRPC
The National Alliance of State Prostate Cancer Coalitions (NASPCC) recommends a baseline prostate specific antigen (PSA) blood test and digital rectal exam (DRE) beginning at age 40 (at 35 if high risk, including African-America Men or men with a certain or indeterminate family history of prostate cancer), and then periodically depending on those results. You should know and keep tract of all your PSA measurements and ANY CHANGE IN PSA should be discussed with your doctor.
The Arizona Prostate Cancer Coalition is here to help you navigate through the jargon and maze of treatment options. Check out our services page for links to support groups, upcoming events and more!
In the News
Looking for in-person or online
prostate cancer events?
Do You Carry A
Genetic Mutation?
Been diagnosed? Get on it now!
Our Helpful Links page offers
a wealth of useful information
Arizona Prostate Cancer Coalition
A proud participant in the
National Alliance of State Prostate Cancer Coalitions
AZPCC and UsTOO participate in Ironwood Cancer & Research Centers Cancer Survivor Breakfast events
In the Community
We are proud to stand with other patient groups in support of the Multi Cancer Early Screening Act legislation.
AZPCC Secretary/Board Member and Cancer Matters President/CEO Renae Linden presents at the New Home Baptist Church Health Ministry's Health is Wealth Expo 2025